Cancer Chemotherapy and Pharmacology

, Volume 23, Issue 6, pp 401–402 | Cite as

Fractionated anthracycline therapy in acute myeloblastic leukaemia in adults

  • Sarah M. Donohue
  • Brian J. Boughton
Short Communication Anthracycline Cardiotoxicity, Myeoloblastic Leukaemia, Adults

Summary

A total of nine adults with newly diagnosed acute myeloblastic leukaemia (AML) and seven with relapsed disease were treated with fractionated daunorubicin in combination with cytosine arabinoside and 6-thioguanine. Remissions were seen in 89% and 57%, respectively. The side effects associated with bolus injections of daunorubicin were much less severe with fractionated treatment, and there was no significant cardiotoxicity despite total doses of up to 1363 mg/m2 daunorubicin. These results show that fractionated anthracyclines are effective in the treatment of AML and that this mode of administration may permit an upward revision of the accepted dose limits for anthracyclines.

Keywords

Cancer Research Cytosine Total Dose Anthracyclines Bolus Injection 

References

  1. 1.
    Blum RH, Carter SK (1974) Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med 80: 249Google Scholar
  2. 2.
    Boughton BJ, Franklin IM, Apperley J, Knight D (1984) Non-cardiotoxic anthracycline regimens in the treatment of acute myeloblastic leukaemia. Br J Haematol 58: 378Google Scholar
  3. 3.
    Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac catheterisation. Ann Intern Med 88: 168Google Scholar
  4. 4.
    Chlebowski T, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR (1980) Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64 (1): 47Google Scholar
  5. 5.
    Gale RP, Foon KA (1986) Acute myeloid leukaemia. Recent advances in therapy (Clinics in haematology, vol 15, no. 3, chap 10). W. B. Saunders, LondonGoogle Scholar
  6. 6.
    Legha SS, Benjamin RS, Mackay B, Ewer M, Wallace S, Valdivieso M, Rasmussen SL, Blumenschein GR, Freidreich E (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133Google Scholar
  7. 7.
    Lenaz L, Page JA (1976) Cardiotoxicity of adriamycin and related anthracyclines. Cancer Treat Rev 3: 111Google Scholar
  8. 8.
    Lewis JP, Meyers FJ, Tanaka L (1985) Daunomycin administered by continuous intravenous infusion is effective in the treatment of acute nonlymphocytic leukaemia. Br J Haematol 61: 261Google Scholar
  9. 9.
    Rees JKH, Gray RG, Swirsky D, Hayhoe FGJ (1986) Principal results of the Medical Research Council's 8th Acute Myeloid Leukaemia Trial. Lancet ii: 1236Google Scholar

Copyright information

© Springer-Verlag 1989

Authors and Affiliations

  • Sarah M. Donohue
    • 1
  • Brian J. Boughton
    • 1
  1. 1.Department of HaematologyQueen Elizabeth HospitalEdgbastonUK

Personalised recommendations